Maruti Suzuki e Vitara India launch: From expected price to features, five key things you need to know

The much-awaited Maruti Suzuki's electric SUV is all set to be launched in the Indian market on December 2, 2025 with ...

Spinal Muscular Atrophy Pipeline Insights Report 2025: Uncovering Breakthrough Drug Candidates Driving Future Market Growth

On 25 November 2025, Novartis Pharmaceuticals conducted a study is to evaluate the safety, tolerability, and efficacy of the two different treatment combinations of tulmimetostat in participants with ...
MedPage Today on MSN

FDA Gives Broad Approval to Gene Therapy for Rare Neurologic Disease

The FDA approved the intrathecal gene therapy onasemnogene abeparvovec (Itvisma) to treat spinal muscular atrophy (SMA) in ...

Mahindra XEV 9S first-drive review: Electrified XUV 700 or more?

The Mahindra XEV 9S arrives as one of the most compelling family EVs in the market today. With prices starting at Rs 19.95 lakh, it undercuts expectat ...
Science Daily

Nanoflowers supercharge stem cells to recharge aging cells

Texas A&M researchers found a way to make stem cells produce double the normal number of mitochondria using nanoflower ...

Scientists Make Breakthrough Toward ‘Recharging’ of Aging Tissues

This approach has the potential to rejuvenate specific tissues affected by mitochondrial decline," author Gaharwar told ...
News Tribune

Whiskers are more than just cute attribute

Whiskers are one of the most distinguishable features about a cat. Although whiskers are typically seen as an adorable attribute, they have multiple purposes to help cats navigate their way through ...

Novartis receives FDA approval for Itvisma(R), the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)

ITVISMA is a prescription gene therapy used to treat adults and children 2 years of age and older with spinal muscular atrophy (SMA). ITVISMA is given as a one-time intrathecal injection. What is the ...

US FDA approves Novartis' gene therapy for rare muscle disorder

The U.S. Food and Drug Administration has approved Novartis' gene therapy for patients with a rare muscle disorder, the drugmaker said on Monday.
Fierce Pharma

Novartis scores FDA approval for new version of SMA gene therapy, prices at $2.59M

Novartis is pricing Itvisma at a wholesale acquisition cost of $2.59 million, a company spokesperson told Fierce Pharma. At ...
WUWM 89.7 FM - Milwaukee's NPR

2025 Kia Telluride SX-Prestige X-Pro AWD review

Five years ago, I named Kia’s Telluride as my Zoomie Vehicle of the Year because it was near perfect. Not much has changed, ...

Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)

Ad hoc announcement pursuant to Art. 53 LR Itvisma (onasemnogene abeparvovec-brve) demonstrated improved motor function and stabilization in patients regardless of SMA treatment history in Phase III ...